Key takeaways
Androxy (fluoxymesterone) and Testopel (testosterone) are both used to treat low testosterone in males, but they have some key differences. Androxy, an androgen, was available in oral form and also used to treat breast cancer in females, but it has been discontinued in the United States. On the other hand, Testopel is a testosterone replacement therapy available as an implantable pellet, which is placed under the skin by a healthcare provider. Testopel is long-acting, requiring implantation every 3 to 6 months, whereas Androxy was taken orally. Additionally, Testopel is not recommended for men with breast or prostate cancer, while Androxy was used to slow the spread of metastatic breast cancer in females. Testopel also has specific risks related to the implantation procedure, such as infection and pellet extrusion, which are not concerns with the discontinued oral Androxy.
